8 completed, 3 terminated, 1 recruiting. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 8, Terminated 3, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Dialysis: new trials by email Literature Review of Dialysis trials Research Report on Dialysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China AP301, AP301 Low Dose - Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis | Phase 3 | Recruiting | Alebund Pharmaceuticals | 264 | 2025-06-13 | 2026-01-29 |
| AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose - ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD) | Phase 3 | Completed | Alebund Pharmaceuticals | 474 | 2023-06-12 | 2025-11-17 |
| Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Teriparatide - Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder | Phase 3 | Completed | Saint Petersburg State University, Russia | 20 | 2021-03-01 | 2022-11-10 |
| Dose-finding Study of MCI-196 colestilan-L, colestilan-M, colestilan-H - Chronic Kidney Disease, Dialysis | Phase 3 | Terminated | Tanabe Pharma Corporation | 10 | 2014-04-01 | 2015-05-27 |
| Long-term Extension Study of MCI-196 colestilan, CBPB - Chronic Kidney Disease, Dialysis | Phase 3 | Terminated | Tanabe Pharma Corporation | 6 | 2013-08-01 | 2015-05-27 |
| Drug Eluting Balloon Angioplasty for Dialysis Access Treatment Percutaneous Transluminal Angioplasty (PTA) - Dialysis, Angioplasty | Phase 2 / Phase 3 | Completed | University of Patras | 40 | 2010-03-01 | 2012-01-23 |
| Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia MCI-196 - Chronic Kidney Disease, Dialysis | Phase 3 | Completed | Tanabe Pharma Corporation | 116 | 2008-12-01 | 2026-01-08 |
| A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia MCI-196, Placebo - Chronic Kidney Disease, Dialysis | Phase 3 | Completed | Tanabe Pharma Corporation | 642 | 2007-12-01 | 2026-01-08 |
| A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia MCI-196, Another Phosphate binder (Sevelamer) - Chronic Kidney Disease, Dialysis | Phase 3 | Completed | Tanabe Pharma Corporation | 632 | 2007-11-01 | 2026-01-07 |
| A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia MCI-196, Placebo - Chronic Kidney Disease, Dialysis | Phase 3 | Completed | Tanabe Pharma Corporation | 245 | 2007-09-01 | 2026-01-08 |
| A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®), Placebo - Chronic Kidney Disease, Dialysis | Phase 3 | Terminated | Tanabe Pharma Corporation | 6 | 2007-05-01 | 2011-11-15 |
| Citrate Anticoagulation vs. Heparin-Coated Dialyzers anticoagulation procedure - Dialysis | Phase 3 | Completed | Universitaire Ziekenhuizen KU Leuven | 33 | 2005-01-01 | 2006-11-03 |
Hyperphosphatemia (9) · Renal Insufficiency, Chronic (9) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Dyslipidemias (1) · Hyperparathyroidism, Secondary (1) · Hypocalcemia (1) · Hypoparathyroidism (1)
Chronic Disease (10) · Disease Attributes (10) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Kidney Diseases (10) · Male Urogenital Diseases (10) · Metabolic Diseases (10) · Nutritional and Metabolic Diseases (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Urogenital Diseases (10) · Urologic Diseases (10) · Phosphorus Metabolism Disorders (9) · Renal Insufficiency (9) · Avitaminosis (1)
cholebine (6) · Sevelamer (2) · Angioplasty (1) · Teriparatide (1)
Tanabe Pharma Corporation (7) · Alebund Pharmaceuticals (2) · Saint Petersburg State University, Russia (1) · Universitaire Ziekenhuizen KU Leuven (1) · University of Patras (1)
United Kingdom (4) · Italy (3) · North Macedonia (3) · Poland (3) · Russia (3) · Serbia (3) · United States (3) · China (2) · Czechia (2) · France (2) · Germany (2) · Hungary (2) · Malaysia (2) · South Africa (2) · Spain (2)
Dimitrios Siablis, MD, PhD (1) · Pieter Evenepoel, MD, PhD (1)
PMID 40576086, PMID 17472846, PMID 22545894, PMID 25575743, PMID 26184491, PMID 26670307, PMID 38189593